PDCD1 and lung carcinoma: The PD-1-inhibiting monoclonal antibodies nivolumab and pembrolizumab have shown favorable activity and good tolerability in clinical trials and have been approved for use in metastatic melanoma (nivolumab, pembrolizumab) and lung cancer (nivolumab) [4].